Ignite Creation Date:
2024-05-06 @ 3:26 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04635605
Status:
UNKNOWN
Last Update Posted:
2022-04-20
First Post:
2020-09-28
Brief Title:
Methylene Blue Treatment of COVID-19
Sponsor:
Fondazione Epatocentro Ticino
Organization:
Fondazione Epatocentro Ticino
Study Overview
Official Title:
Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV2- Affected Patients a Phase 2 Randomized Placebo- Controlled Single Blind Clinical Trial
Status:
UNKNOWN
Status Verified Date:
2022-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Despite enormous progress in understanding COVID-19 there is little evidence that a solution therapeutic or preventive is close to being achieved Repurposing of well known widely available drugs represent an attractive approach to speed up availability of active treatments Such substances as ie hydroxychloroquine and others are already under investigation and in widespread off label use For many reasons Methylene blue MB the oldest synthetic substance in medicine 1876 synthesized by BASF is such a promising candidate for an active treatment against SARS-CoV-2 infected people and for COVID-19 patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None